✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Biontech SE

Common Name
Biontech
Country
Germany
Sector
Healthcare
Industry
Biotechnology
Employees
6,772
Ticker
BNTX
Exchange
NASDAQ/NGS
Description
BioNTech SE - Depositary Receipt (Common Stock) represents shares in BioNTech SE, a Germany-based biotechnology company specializing in next-generation immunotherapies. The company develops transforma...

Biontech's Financial Statements Preview

Below are the financial statements of Biontech, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of EUR
2024 as of 2024-12-31
2023 as of 2023-12-31
Assets
Non-current assets
Goodwill
380.6a
362.5a
Other intangible assets
790.4a
804.1a
Property, plant and equipment
935.3a
757.2a
Right-of-use assets
248.1a
214.4a
Contract assets
9.8a
0a
Other financial assets
1,254a
1,176.1a
Other non-financial assets
26.3a
83.4a
Deferred tax assets
81.7a
81.3a
Total non-current assets
3,726.2a
3,479a
Current assets
Inventories
283.3a
357.7a
Trade and other receivables
1,463.9a
2,155.7a
Contract assets
10a
4.9a
Other financial assets
7,021.7a
4,885.3a
Other non-financial assets
212.7a
280.9a
Income tax assets
50a
179.1a
Cash and cash equivalents
9,761.9a
11,663.7a
Total current assets
18,803.5a
19,527.3a
Total assets
22,529.7a
23,006.3a
Equity and liabilities
Equity
Share capital
248.6a
248.6a
Capital reserve
1,398.6a
1,229.4a
Treasury shares
-8.6a
-10.8a
Retained earnings
19,098a
19,763.3a
Other reserves
-1,325.5a
-984.6a
Total equity
19,411.1a
20,245.9a
Non-current liabilities
Lease liabilities, loans and borrowings
214.7a
191a
Other financial liabilities
46.9a
38.8a
Provisions
20.9a
8.8a
Contract liabilities
183a
398.5a
Other non-financial liabilities
87.5a
13.1a
Deferred tax liabilities
42.4a
39.7a
Total non-current liabilities
595.4a
689.9a
Current liabilities
Lease liabilities, loans and borrowings
39.5a
28.1a
Trade payables and other payables
426.7a
354a
Other financial liabilities
1,443.4a
415.2a
Income tax liabilities
4.5a
525.5a
Provisions
144.8a
269.3a
Contract liabilities
294.9a
353.3a
Other non-financial liabilities
169.4a
125.1a
Total current liabilities
2,523.2a
2,070.5a
Total liabilities
3,118.6a
2,760.4a
Total equity and liabilities
22,529.7a
23,006.3a
Limited Data Preview
You are viewing a limited preview of Biontech’s balance sheet data. The reported financial values are complete. The full dataset, available for download, additionally includes structured metadata for each line item, such as line item role (line item, subtotal, total) and financial classification (e.g., assets, liabilities, equity, revenue, expenses).
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Biontech’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Biontech’s data sources below and access millions more through our Disclosure Search.

a. Biontech's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?